Vaginal delivery after improvement in COVID-19 by monoclonal antibody treatment: A case report and literature review |
| |
| Affiliation: | 1. Department of Rheumatology, Minami-Nagano Medical Center, Shinonoi General Hospital, 666-1 Shinonoi, Nagano-city, Nagano, 388-8004, Japan;2. Department of Internal Medicine, Minami-Nagano Medical Center, Shinonoi General Hospital, 666-1 Shinonoi, Nagano-city, Nagano, 388-8004, Japan;3. Department of General Medicine, Minami-Nagano Medical Center, Shinonoi General Hospital, 666-1 Shinonoi, Nagano-city, Nagano, 388-8004, Japan;4. Department of Obstetrics and Gynecology, Minami-Nagano Medical Center, Shinonoi General Hospital, 666-1 Shinonoi, Nagano-city, Nagano, 388-8004, Japan;5. Laboratory of Infectious Diseases, Graduate School of Infection Control Sciences & ōmura Satoshi Memorial Institute, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan |
| |
| Abstract: | As the COVID-19 pandemic persists, pregnant women have been increasingly affected worldwide. Women during the last trimester of pregnancy are susceptible to severe COVID-19, and there are many challenges towards its treatment. Monoclonal antibody treatment (MAT) is approved for COVID-19 patients to reduce disease severity. However, there are few reports on the MAT in perinatal women. Herein, we report a 39-year-old pregnant female (36 weeks and 6 days of gestation) with improvement in COVID-19 pneumonia after treatment with casiribimab/imdevimab, resulting in successful vaginal delivery (a 2.868 kg male newborn), along with a literature review. Early diagnosis and treatment of pregnant women with COVID-19 are important. Infectious diseases doctors and/or obstetricians should be aware of the MAT option administered to perinatal COVID-19 women to reduce disease severity. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
